A Study to Evaluate the Effectiveness of Intravenous Iron Sucrose in Patients with Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

Overview

Información sobre este estudio

This study aims to investigate whether the treatment of non-anemic iron deficiency with intravenous iron sucrose will result in decreased symptom reporting and improved cardiovascular indices in patients with Postural Orthostatic Tachycardia syndrome (POTS).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Patients (age 12 to years and older) with chronic (> 3 months) symptoms of orthostatic intolerance, including but not limited to lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and heart palpitations. 
  • Symptomatic orthostatic heart rate increment ≥ 30 bpm if >19 years old or ≥ 40 bpm if < 19 years old during a 10 minute 70 degree head up tilt study
  • Presence of non-anemic iron deficiency, defined as serum ferritin levels < 20 ug/L with hemoglobin no less than 1 gm/dL below the normal reference range as defined for age and gender.
  • Consent obtained from responsible guardian AND from subjects, 12-17 years of age.
  • Consent obtained for subjects 18 years of age and older.

Exclusion Criteria:

  • Orthostatic hypotension (decrease of systolic BP > 30 mmHg and/or diastolic BP > 15mmHg within 3 minutes of 70 degree head up tilt study).
  • Pregnant or lactating females
  • The presence of failure of other organ systems or systemic illness that can affect autonomic function.
  • Concomitant therapy with anticholinergic, alpha-adrenergic antagonists, beta-adrenergic antagonists or other medications which could interfere with autonomic testing.  Patients may participate if the potentially interfering medication is held for five half-lives prior to the study.
  • Laboratory evidence of anemia or iron overload.
  • Personal history of hematochromatosis or first degree relative with hematochromatosis.
  • Known sensitivity to Venofer® (iron sucrose injection, USP) or other intravenous iron preparation.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Kamal Shouman, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20513940

Mayo Clinic Footer